KEGG   DRUG: Durvalumab
Entry
D10808                      Drug                                   
Name
Durvalumab (USAN/INN);
Durvalumab (genetical recombination) (JAN);
Imfinzi (TN)
Product
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYWMSWVRQA PGKGLEWVAN IKQDGSEKYY
VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG GWFGELAFDY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPEFEG
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPASIEKTI SKAKGQPREP QVYTLPPSRE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQRVS SSYLAWYQQK PGQAPRLLIY DASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSLPWTFG QGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H96, H148-H204, H224-L215, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'96, H'148-H'204, H'224-L'-225, H'265-H'325, H'371-H'429, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FF03
Product: D10808<JP/US>
Efficacy
Antineoplastic, Anti-PD-L1 antibody
  Disease
Non-small cell lung cancer [DS:H00014]
Small cell lung cancer [DS:H00013]
Biliary tract cancers [DS:H00046 H00047]
Hepatocellular carcinoma [DS:H00048]
  Type
Monoclonal antibody
Target
PDL1 (CD274) [HSA:29126] [KO:K06745]
  Pathway
hsa04514  Cell adhesion molecules
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
     L01FF03 Durvalumab
      D10808  Durvalumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Durvalumab
    D10808  Durvalumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10808  Durvalumab (USAN/INN); Durvalumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D10808  Durvalumab
Drug classes [BR:br08332]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D10808  Durvalumab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDL1 (CD274)
     D10808  Durvalumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10808
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10808
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10808
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10808
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10808
Other DBs
CAS: 1428935-60-7
PubChem: 319075068
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system